Bile duct cancer
Drug research and approvals for bile duct cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 232 studies of bile duct cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.
- Recruiting worldwide: 232
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Photodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent for Unresectable…NCT07916870 · Not applicable · Zhai Wenlong · starts May 30, 2025
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic…NCT07847710 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Sep 30, 2026
- HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICCNCT07841574 · Phase 2 · Lianghe Lu · starts Jun 11, 2026
- HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar CholangiocarcinomaNCT07795619 · Not applicable · Tianjin Medical University Cancer Institute and Hospital · starts Apr 1, 2026
- Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive CholangiocarcinomaNCT07786766 · Phase 2 · Haitao Zhao, MD · starts Aug 20, 2026
- Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaNCT07780838 · Phase 2 · Ohio State University Comprehensive Cancer Center · starts Nov 1, 2026
- Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic CholangiocarcinomaNCT07766187 · Phase 2 · University of Wisconsin, Madison · starts Nov 1, 2026
- 68Ga-SorB PET/CT Imaging in Patients With Solid TumorsNCT07760012 · Not applicable · Peking University Third Hospital · starts Aug 13, 2026
Phase 3 1
- Porfimer sodiumDNA inhibitor
Phase 2 12 of 28
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- CisplatinDNA inhibitor
- OxaliplatinDNA inhibitor
- FluorouracilThymidylate synthase inhibitor
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- CapecitabineThymidylate synthase inhibitor
- CarboplatinDNA inhibitor
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- IxabepiloneTubulin inhibitor
Phase 1 or earlier 3
- PembrolizumabProgrammed cell death protein 1 inhibitor
- CDX-1140Tumor necrosis factor receptor superfamily member 5 agonist
- Octanoic acid
How its trials ended
205 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 46 whose ending is known, 24% met their primary endpoint, 11% missed it and 65% stopped early.
- Completed, result not reported7537%
- Ongoing5326%
- Status unknown3115%
- Stopped: other or unclear147%
- Met its primary endpoint115%
- Stopped: enrollment or feasibility84%
- Missed its primary endpoint52%
- Stopped: lack of efficacy31%
- Stopped: sponsor or business decision31%
- Stopped: safety1<1%
- Stopped: funding1<1%
| Feb 6, 2025 | 3-bromopyruvateTreatment of liver and intrahepatic bile duct cancer | Cage Pharmaceuticals, Inc. | Designated |
| Nov 26, 2024 | Monoclonal antibody targeting CD36Treatment of liver and intrahepatic bile duct cancer | Pilatus Biosciences Inc. | Designated |
| Nov 30, 2021 | An ADC drug against CLDN18.2, containing a recombinant…Treatment of Cholangiocarcinoma (intrahepatic bile duct cancer) | LaNova Medicines Limited | Designated |
| Apr 16, 2013 | Opioid growth factorTreatment of liver and intrahepatic bile duct cancer | Primocure Pharma, Inc. | Designated |
| Mar 5, 2013 | 3-bromopyruvateTreatment of liver and intrahepatic bile duct cancer | KoDiscovery, LLC | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA